Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma

• Published in: PloS one 2015-10, Vol.10 (10), p.e0140830-e0140830
• Main Authors: Kanoun, Salim, Tal, Ilan, Berriolo-Riedinger, Alina, Rossi, Cédric, Riedinger, Jean-Marc, Vrigneaud, Jean-Marc, Legrand, Louis, Humbert, Olivier, Casasnovas, Olivier, Brunotte, François, Cochet, Alexandre
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Chemotherapy; Computer programs; Consent; Diagnosis; Disease-Free Survival; Female; Fluorine isotopes; Follow-Up Studies; Glucose; Glucose-6-Phosphate - administration & dosage; Glucose-6-Phosphate - analogs & derivatives; Hematology; Hodgkin Disease - diagnostic imaging; Hodgkin Disease - mortality; Hodgkin's disease; Hodgkin's lymphoma; Humans; Image Processing, Computer-Assisted - methods; Liver; Lymphoma; Male; Mathematical analysis; Measurement; Medical diagnosis; Medical imaging; Medical prognosis; Metabolism; Methods; Middle Aged; Non-Hodgkin's lymphomas; Nuclear medicine; Patient outcomes; Patients; PET imaging; Positron emission; Positron emission tomography; Predictions; Predictive Value of Tests; Prognosis; Radiography; Software; Software development tools; Studies; Survival; Survival Rate; Technology application; Tomography; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0140830

To investigate the respective influence of software tool and total metabolic tumor volume (TMTV0) calculation method on prognostic stratification of baseline 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography ([18F]FDG-PET) in newly diagnosed Hodgkin lymphoma (HL). 59 patients with newly diagnosed HL were retrospectively included. [18F]FDG-PET was performed before any treatment. Four sets of TMTV0 were calculated with Beth Israel (BI) software: based on an absolute threshold selecting voxel with standardized uptake value (SUV) >2.5 (TMTV02.5), applying a per-lesion threshold of 41% of the SUV max (TMTV041) and using a per-patient adapted threshold based on SUV max of the liver (>125% and >140% of SUV max of the liver background; TMTV0125 and TMTV0140). TMTV041 was also determined with commercial software for comparison of software tools. ROC curves were used to determine the optimal threshold for each TMTV0 to predict treatment failure. Median follow-up was 39 months. There was an excellent correlation between TMTV041 determined with BI and with the commercial software (r = 0.96, p